Johnson & Johnson (JNJ) was Reiterated by Piper Jaffray to “Neutral” according to the research note released today. The brokerage firm has raised the Price Target to $ 106 from a previous price target of $105 . Piper Jaffray advised their investors in a research report released on Apr 20, 2016.
Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by RBC Capital Mkts on Apr 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $122 .Company shares were Reiterated by RBC Capital Mkts on Apr 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 122 from a previous price target of $114 .Johnson & Johnson was Upgraded by Goldman to ” Neutral” on Mar 14, 2016.
On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Apr 19, 2016. Analyst had a consensus of $1.65. The company had revenue of $17482.00 million for the quarter, compared to analysts expectations of $17491.02 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.
Johnson & Johnson opened for trading at $110 and hit $111.1 on the upside on Monday, eventually ending the session at $110.93, with a gain of 0.68% or 0.75 points. The heightened volatility saw the trading volume jump to 77,72,549 shares. Company has a market cap of $306,096 M.
In a different news, on Feb 4, 2016, Peter Fasolo (VP, Global Human Resources) sold 151,385 shares at $104.11 per share price. According to the SEC, on Nov 24, 2015, Michael H Ullmann (VP, General Counsel) sold 17,650 shares at $102.47 per share price. On Nov 4, 2015, Dominic J Caruso (VP, Finance; CFO) sold 20,569 shares at $102.21 per share price, according to the Form-4 filing with the securities and exchange commission.
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.